KR20190019660A - A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion - Google Patents
A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion Download PDFInfo
- Publication number
- KR20190019660A KR20190019660A KR1020170104866A KR20170104866A KR20190019660A KR 20190019660 A KR20190019660 A KR 20190019660A KR 1020170104866 A KR1020170104866 A KR 1020170104866A KR 20170104866 A KR20170104866 A KR 20170104866A KR 20190019660 A KR20190019660 A KR 20190019660A
- Authority
- KR
- South Korea
- Prior art keywords
- licorice
- extract
- dandelion
- yellow dandelion
- yellow
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 title claims abstract description 45
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 title claims abstract description 36
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 title claims abstract description 36
- 229940010454 licorice Drugs 0.000 title claims abstract description 36
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 17
- 239000000284 extract Substances 0.000 title claims description 46
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 title claims description 44
- 240000001949 Taraxacum officinale Species 0.000 title claims description 8
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims description 6
- 208000010643 digestive system disease Diseases 0.000 title description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 title description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 67
- 235000020691 dandelion extract Nutrition 0.000 claims abstract description 36
- 208000007882 Gastritis Diseases 0.000 claims abstract description 25
- 230000036541 health Effects 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 11
- 241000202807 Glycyrrhiza Species 0.000 claims abstract description 9
- 241000245665 Taraxacum Species 0.000 claims description 39
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 37
- 230000002496 gastric effect Effects 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 13
- 201000005917 gastric ulcer Diseases 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 10
- 206010017856 Gastritis alcoholic Diseases 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 201000005988 alcoholic gastritis Diseases 0.000 claims description 9
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims description 7
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims description 7
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 7
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 7
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 235000006754 Taraxacum officinale Nutrition 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000023652 chronic gastritis Diseases 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 229940067866 dandelion extract Drugs 0.000 abstract description 24
- 239000001845 taraxacum officinale leaf extract Substances 0.000 abstract description 24
- 230000002195 synergetic effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 description 26
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 24
- 229940051810 licorice root extract Drugs 0.000 description 24
- 235000020725 licorice root extract Nutrition 0.000 description 24
- 238000011282 treatment Methods 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 229940069445 licorice extract Drugs 0.000 description 15
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 14
- 108010082126 Alanine transaminase Proteins 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 13
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 229940107681 dandelion root extract Drugs 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 7
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 240000003768 Solanum lycopersicum Species 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000009858 acid secretion Effects 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000008960 ketchup Nutrition 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 244000044283 Toxicodendron succedaneum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 229950004535 rebamipide Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 감초 및 노랑민들레 추출물을 유효성분으로 함유하는 알코올성 위장관질환의 예방, 개선 또는 치료용 조성물에 관한 것으로, 더욱 상세하게는 알코올로 유발된 위 조직의 염증 완화에 상승효과(synergistic effect)를 나타내는 감초 및 노랑민들레 추출물의 혼합물을 이용하여 알코올성 위장관질환의 예방, 개선 또는 치료용 약학적 조성물 및 건강기능식품을 제공한다.The present invention relates to a composition for preventing, improving or treating an alcoholic gastrointestinal tract disease containing licorice and yellow dandelion extract as an active ingredient, and more particularly, to a composition for preventing, improving or treating an alcoholic gastrointestinal tract disease, A pharmaceutical composition for preventing, ameliorating or treating alcoholic gastrointestinal diseases, and a health functional food using the mixture of licorice and yellow dandelion extracts.
우리나라의 경우 20세 이상 성인 남자의 음주율은 83.3%로 매우 높고 여성의 음주율 또한 54.9%로 급격히 증가하는 추세에 있으며, 잘못된 음주문화로 인하여 과음에 심각하게 노출되어 있다. 알코올의 과다 섭취로 인한 폐해는 위염 및 간질환을 비롯하여 각종 질환의 병인이 됨은 물론 개인, 가정, 사회의 정서와 생활에 부정적인 영향을 미침으로써 국가적으로 막대한 경제, 사회적 손실을 야기하고 있다.In Korea, the drinking rate of men over 20 years old is very high (83.3%), and the rate of women drinking is also rapidly increasing to 54.9%, which is seriously exposed to excessive drinking due to wrong drinking culture. The harmful effects of excessive alcohol intake are not only a cause of various diseases such as gastritis and liver disease, but also have a negative impact on the emotions and lives of individuals, families and society, resulting in enormous national and economic losses.
알코올성 위염은 알코올로 인한 만성적인 자극에 의해 위 점막이 손상된 상태를 일컫는다. 알코올성 위염에 걸리면 소화가 잘 되지 않고 쓰린 느낌을 호소하는 경우도 있지만 대부분 특별한 증상이 없다가 내시경 검사와 초음파 검사를 통해 심각한 증상이 발견된다. 만성적으로 술을 마시는 경우 위염뿐만 아니라 췌장이나 간 등도 손상시켜 관련질환을 유발하며, 또한 식도암, 위암, 대장암의 위험도 높아진다.Alcoholic gastritis refers to a state in which the gastric mucosa is damaged by chronic stimuli due to alcohol. Alcoholic gastritis is not easy to digest and sometimes feel sore, but most of the symptoms are not specific symptoms through endoscopy and ultrasonography is found. Chronic drinking does not only lead to gastritis, but also damage the pancreas and liver, leading to related diseases, and also increases the risk of esophageal cancer, stomach cancer and colon cancer.
특히, 알코올로 인한 위염 및 위궤양은 가장 주의를 요하는데, 알코올은 위벽의 세포를 자극해 산 분비를 증가시키며, 과도한 알코올 섭취는 위점막의 부종을 발생시켜 출혈을 일으키고 염증세포들의 생성을 유도한다. 또한, 산화적 스트레스로 인한 괴사 혹은 세포사멸을 유도하여 위점막을 손상시키고, 위출혈이 나타나게 된다.In particular, gastritis and gastric ulceration due to alcohol require the most attention. Alcohol stimulates the cells of the gastric wall to increase acid secretion. Excessive alcohol consumption causes edema of the gastric mucosa, leading to bleeding and induction of inflammatory cells . In addition, it induces necrosis or cell death due to oxidative stress, damaging the gastric mucosa and causing gastrointestinal bleeding.
종래의 위염 및 위궤양의 치료제로는 과다 분비된 위산을 중화시키는 제산제(antacid), 산 분비 억제 목적의 히스타민 길항제(histamine antagonist), 프로톤 펌프 저해제(proton pump inhibitor), 콜린 억제제, 위내막의 내성을 증가시키고 회복을 돕는 위점막보호제 등이 있다. 다만, 이와 같은 치료제들은 합성 의약품으로 식욕감퇴, 무력감, 알레르기 등의 부작용이 발생하는 문제점이 있었다.Conventional treatments for gastritis and gastric ulcers include antacids that neutralize excess secreted acid, histamine antagonists to inhibit acid secretion, proton pump inhibitors, cholinergic inhibitors, and resistance to gastric lining And gastric mucosal protective agents that help increase recovery. However, such therapeutic agents are synthetic drugs and have side effects such as loss of appetite, weakness, and allergy.
이에 따라, 대한민국 공개특허 제10-2009-0046425호(천마 추출물을 함유하는 위염 또는 위궤양의 예방 또는 치료용 조성물), 대한민국 등록특허 제10-1091025호(복분자 추출물을 함유하는 비스테로이드성 항염증제에 의해 유발된 위염 및 위궤양 예방 및 치료용 조성물), 대한민국 공개특허 제10-2012-0051904호(옻나무 추출물을 포함하는 위염 및 위궤양 치료제 조성물), 대한민국 등록특허 제10-1204981호(고로쇠 수액을 함유하는 위염 및 위궤양의 예방 및 치료용 조성물) 등 위염 및 위궤양의 예방 및 치료 효과가 있는 천연 추출물에 대한 관심이 높아지고 있다. Accordingly, Korean Patent Laid-Open No. 10-2009-0046425 (composition for preventing or treating gastritis or gastric ulcer containing Ganoderma extract), Korean Patent No. 10-1091025 (non-steroidal anti-inflammatory agent containing bokbunja extract Korean Patent Laid-Open No. 10-2012-0051904 (composition for treating gastritis and gastric ulcer including Rhus verniciflua extract), Korean Patent No. 10-1204981 (composition for preventing and treating gastritis containing gonorrhea And compositions for the prevention and treatment of gastric ulcers) have been increasingly attracted to natural extracts having preventive and therapeutic effects of gastritis and gastric ulcer.
이러한 배경하에, 본 발명자들은 감초와 노랑민들레 추출물의 혼합물이 알코올성 위장관질환의 완화에 상승효과를 나타냄을 확인하고 본 발명을 완성하였다.Under these circumstances, the inventors of the present invention have confirmed that a mixture of licorice and yellow dandelion extracts has a synergistic effect on the alleviation of alcoholic gastrointestinal diseases, and completed the present invention.
본 발명은 상기와 같은 문제점을 해결하기 위해 안출된 것으로, 감초 및 노랑민들레 추출물의 혼합물을 이용하여 알코올성 위장관질환을 예방, 개선 또는 치료하기 위한 조성물을 제공하는데 목적이 있다.Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to provide a composition for preventing, ameliorating or treating alcoholic gastrointestinal tract diseases using a mixture of licorice and yellow dandelion extract.
상술한 과제를 해결하기 위해, 본 발명은 감초(Glycyrrhiza uralensis) 및 노랑민들레(Taraxacum officinale) 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위장관질환의 예방 또는 치료용 약학적 조성물을 제공한다.In order to solve the above-mentioned problems, the present invention relates to a method for producing Glycyrrhiza the present invention provides a pharmaceutical composition for preventing or treating an alcoholic gastrointestinal tract disease comprising, as an active ingredient, a mixture of uralensis and Taraxacum officinale extract.
본 발명은 또한, 감초(Glycyrrhiza uralensis) 및 노랑민들레(Taraxacum officinale) 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위장관질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention also relates to the use of Glycyrrhiza uralensis ) and yellow dandelion ( Taraxacum The present invention provides a health functional food composition for preventing or ameliorating an alcoholic gastrointestinal tract disease, which comprises a mixture of an extract of Lactobacillus officinale as an active ingredient.
본 발명의 바람직한 일실시예에 따르면, 상기 감초의 부위는 뿌리이고, 상기 노랑민들레의 부위는 지상부일 수 있다.According to a preferred embodiment of the present invention, the licorice root is a root, and the yellow dandelion is a ground.
본 발명의 바람직한 다른 일실시예에 따르면, 상기 감초 및 노랑민들레 추출물은 물, C1~C4의 알코올 또는 이들의 혼합용매로 추출할 수 있다.According to another preferred embodiment of the present invention, the licorice and yellow dandelion extracts can be extracted with water, a C 1 to C 4 alcohol or a mixed solvent thereof.
본 발명의 바람직한 또 다른 일실시예에 따르면, 상기 감초와 노랑민들레 추출물은 1:0.25 내지 1:4의 중량비로 함유될 수 있다.According to another preferred embodiment of the present invention, the licorice and yellow dandelion extracts may be contained in a weight ratio of 1: 0.25 to 1: 4.
본 발명의 바람직한 다른 일실시예에 따르면, 상기 알코올성 위장관질환은 알코올에 의해 유도된 급성 위점막 손상, 위궤양, 급성 위염 및 만성 위염으로 이루어진 군으로부터 선택한 1종 이상일 수 있다.According to another preferred embodiment of the present invention, the alcoholic gastrointestinal disorder may be at least one selected from the group consisting of acute gastric mucosal injury induced by alcohol, gastric ulcer, acute gastritis, and chronic gastritis.
본 발명에 따른 감초 및 노랑민들레 추출물을 특정 중량비 범위로 혼합한 조성물은 알코올에 의해 손상된 위 조직의 염증 완화에 대한 상승효과가 우수하여 알코올성 위염 또는 위궤양을 예방, 개선 또는 치료하는데 유용하다. 또한, 상기 본 발명의 혼합 조성물은 간 조직에서 GOT 및 GPT의 활성을 저해하는 효과가 있어, 추가로 알코올성 간 손상에 대한 예방 효과를 나타낸다.The composition comprising the licorice and yellow dandelion extracts according to the present invention in a specific weight ratio range is useful for preventing, ameliorating or treating alcoholic gastritis or gastric ulcer because of its synergistic effect on alleviating inflammation of gastric tissues damaged by alcohol. In addition, the mixed composition of the present invention has an effect of inhibiting the activity of GOT and GPT in liver tissue and further shows a preventive effect against alcoholic liver damage.
나아가, 본 발명의 조성물은 천연물 소재의 추출물을 유효성분으로 하여 인체에 안전하고, 부작용이 적어 의약품, 의약외품 및 건강기능식품등의 개발에 소재로 적합하다.Furthermore, the composition of the present invention is safe as a human body and has few side effects, and is suitable as a material for the development of medicines, quasi-drugs and health functional foods.
도 1은 알코올 투여로 위염이 유발된 쥐의 위 조직에서 감초와 노랑민들레 추출물을 다양한 중량비로 혼합한 조성물의 처리에 따른 염증 완화 정도를 보여주는 사진이다.
도 2는 도 1의 결과를 바탕으로 각 군의 위 염증 발생 면적을 백분율로 계산하여 나타낸 그래프이다.
도 3은 알코올 투여로 위염이 유발된 쥐의 위 조직에서 감초와 노랑민들레 추출물을 다양한 중량비로 혼합한 조성물의 처리에 따른 iNOS(inducible nitric oxide synthase) 단백질의 발현 억제 효과를 나타낸 그래프이다.
도 4는 알코올 투여로 간 손상을 일으킨 쥐에서 감초와 노랑민들레 추출물을 다양한 중량비로 혼합한 조성물의 처리에 따른 GOP 수치(좌) 및 GPT 수치(우) 저해 효과를 나타낸 그래프이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a photograph showing the degree of inflammation relief according to the treatment of a composition in which licorice and yellow dandelion extract are mixed at various weight ratios in gastric mucosa induced gastritis by alcohol administration.
FIG. 2 is a graph showing the incidence of gastric inflammation in each group as a percentage, based on the results of FIG. 1; FIG.
FIG. 3 is a graph showing the effect of suppressing the expression of iNOS (inducible nitric oxide synthase) protein by treatment of a composition comprising licorice and yellow dandelion extract at various weight ratios in rat gastric tissues induced by gastric administration by alcohol administration.
FIG. 4 is a graph showing the inhibitory effects of GOP values (left) and GPT values (right) according to treatment of a composition in which licorice and yellow dandelion extracts were mixed at various weight ratios in rats caused by alcohol administration.
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
상술한 바와 같이, 종래의 위염 및 위궤양의 치료제로는 과다 분비된 위산을 중화시키는 제산제(antacid), 산 분비 억제 목적의 히스타민 길항제(histamine antagonist), 프로톤 펌프 저해제(proton pump inhibitor), 콜린 억제제, 위내막의 내성을 증가시키고 회복을 돕는 위점막보호제 등이 있다. 다만, 이와 같은 치료제들은 합성 의약품으로 식욕감퇴, 무력감, 알레르기 등의 부작용이 발생하는 문제점이 있어 부작용이 없는 천연 추출물을 이용한 위염 또는 위궤양 치료제에 대한 개발이 지속적으로 요구되고 있다.As described above, conventional therapeutic agents for gastritis and gastric ulcer include antacid that neutralizes excess secreted acid, histamine antagonist for suppressing acid secretion, proton pump inhibitor, choline inhibitor, And gastric mucosal protective agents to increase the tolerance of gastric lining and to help recovery. However, such therapeutic agents are synthetic medicines, and side effects such as loss of appetite, helplessness, allergy, and the like occur. Therefore, development of gastritis or gastric ulcer treatment using natural extracts without side effects is continuously required.
이에, 본 발명자들은 감초와 노랑민들레 추출물의 혼합물을 유효성분으로 함유하는 조성물을 제공함으로써 상술한 문제의 해결방안을 모색하였다. 본 발명에 따른 감초 및 노랑민들레 추출물을 특정 중량비 범위로 혼합한 조성물은 알코올에 의해 손상된 위 조직의 염증 완화에 대한 상승효과가 우수하여 알코올성 위염 또는 위궤양을 예방, 개선 또는 치료하는데 유용하다. 또한, 상기 본 발명의 혼합 조성물은 알코올에 의해 손상된 간 조직에서 GOT 및 GPT의 활성을 저해하는 효과가 있어, 추가로 알코올성 간 손상을 개선시킬 수 있다.Accordingly, the present inventors sought a solution to the above-mentioned problem by providing a composition containing a mixture of licorice and a yellow dandelion extract as an active ingredient. The composition comprising the licorice and yellow dandelion extracts according to the present invention in a specific weight ratio range is useful for preventing, ameliorating or treating alcoholic gastritis or gastric ulcer because of its synergistic effect on alleviating inflammation of gastric tissues damaged by alcohol. In addition, the mixed composition of the present invention has an effect of inhibiting the activities of GOT and GPT in liver tissues damaged by alcohol, and can further improve alcoholic liver damage.
본 발명에서 사용되는 용어는 다음과 같이 정의된다.The terms used in the present invention are defined as follows.
용어 “약학적 조성물(pharmaceutical composition)”은 본 발명의 감초와 노랑민들레 추출물의 혼합물에 희석제 또는 담체와 같은 다른 화학 성분들을 혼합한 혼합물을 의미한다.The term " pharmaceutical composition " means a mixture of a mixture of licorice and yellow dandelion extract of the present invention with other chemical components such as diluent or carrier.
용어 “담체(carrier)”는 세포 또는 조직 내로의 화합물의 부가를 용이하게 하는 화합물로 정의된다. 예를 들어, 디메틸술폭사이드(DMSO)는 생물체의 세포 또는 조직 내로의 많은 유기 화합물들의 투입을 용이하게 하는 통상 사용되는 담체이다.The term " carrier " is defined as a compound that facilitates the addition of a compound into a cell or tissue. For example, dimethylsulfoxide (DMSO) is a commonly used carrier that facilitates the introduction of many organic compounds into cells or tissues of an organism.
용어 “희석제(diluent)”는 대상 화합물의 생물학적 활성 형태를 안정화시킬 뿐만 아니라, 화합물을 용해시키게 되는 물에서 희석되는 화합물로 정의된다. 버퍼 용액에 용해되어 있는 염은 당해 분야에서 희석제로 사용된다. 통상 사용되는 버퍼 용액은 포스페이트 버퍼 식염수이며, 이는 인간 용액의 염 상태를 모방하고 있기 때문이다. 버퍼 염은 낮은 농도에서 용액의 pH를 제어할 수 있기 때문에, 버퍼 희석제가 화합물의 생물학적 활성을 변형하는 일은 드물다.The term " diluent " is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but also dilutes in water to which the compound is dissolved. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, since it mimics the salt state of the human solution. Since buffer salts can control the pH of the solution at low concentrations, buffer diluents rarely modify the biological activity of the compounds.
용어 “치료”는 이롭거나 바람직한 임상적 결과를 수득하기 위한 접근을 의미한다. 본 발명의 목적을 위해서, 이롭거나 바람직한 임상적 결과는 비제한적으로, 증상의 완화, 질병 범위의 감소, 질병 상태의 안정화(즉, 악화되지 않음), 질병 진행의 지연 또는 속도의 감소, 질병 상태의 개선 또는 일시적 완화 및 경감 (부분적이거나 전체적으로), 검출가능하거나 또는 검출되지 않거나의 여부를 포함한다. 또한, “치료”는 치료를 받지 않았을 때 예상되는 생존율과 비교하여 생존율을 늘이는 것을 의미할 수도 있다. “치료”는 치료학적 치료 및 예방적 또는 예방조치 방법 모두를 가리킨다. 상기 치료들은 예방되는 장애뿐만 아니라 이미 발생한 장애에 있어서 요구되는 치료를 포함한다. 질병을 “완화(alleviating)”하는 것은 치료를 하지 않은 경우와 비교하여, 질병상태의 범위 및/또는 바람직하지 않은 임상적 징후가 감소되거나 및/또는 진행의 시간적 추이(time course)가 늦춰지거나 길어지는 것을 의미한다.The term " treatment " means an approach to obtaining beneficial or desired clinical results. For purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stabilization (i.e., not worsening) of the disease state, (Either partially or totally), detectable or undetected, whether or not an improvement or temporary relief or reduction Also, " treatment " may mean increasing the survival rate compared to the expected survival rate when not receiving treatment. &Quot; Treatment " refers to both therapeutic treatment and prophylactic or preventative measures. Such treatments include treatments required for disorders that have already occurred as well as disorders to be prevented. "Alleviating" a disease may result in a reduction in the extent of the disease state and / or undesirable clinical symptoms and / or a slower or longer time course of the progression, It means to lose.
본 발명에서 사용되는 모든 기술용어는, 달리 정의되지 않는 이상, 본 발명의 관련 분야에서 통상의 당업자가 일반적으로 이해하는 바와 같은 의미로 사용된다. 또한 본 명세서에는 바람직한 방법이나 시료가 기재되나, 이와 유사하거나 동등한 것들도 본 발명의 범주에 포함된다.All technical terms used in the present invention are used in the sense that they are generally understood by those of ordinary skill in the relevant field of the present invention unless otherwise defined. Also, preferred methods or samples are described in this specification, but similar or equivalent ones are also included in the scope of the present invention.
본 발명은 감초(Glycyrrhiza uralensis) 및 노랑민들레(Taraxacum officinale) 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위장관질환의 예방 또는 치료용 약학적 조성물을 제공한다.The present invention relates to the use of Glycyrrhiza uralensis ) and yellow dandelion ( Taraxacum The present invention also provides a pharmaceutical composition for preventing or treating an alcoholic gastrointestinal tract disease, which comprises a mixture of an extract of Lactobacillus officinale as an active ingredient.
또한, 본 발명은 감초(Glycyrrhiza uralensis) 및 노랑민들레(Taraxacum officinale) 추출물의 혼합물을 유효성분으로 함유하는 알코올성 위장관질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention relates to the use of Glycyrrhiza uralensis ) and yellow dandelion ( Taraxacum The present invention provides a health functional food composition for preventing or ameliorating an alcoholic gastrointestinal tract disease, which comprises a mixture of an extract of Lactobacillus officinale as an active ingredient.
감초는 감초속(Glycyrrhiza)에 속하는 다년생 초본식물을 의미하며, 본 발명에서 사용된 감초는 농촌진흥청에서 개발한 ‘원감 (Glycyrrhiza uralensis)’으로, 만주 감초(Glycyrrhiza uralensis Fische)와 유럽 감초 (Glycyrrhiza glabra Linne)의 기능성을 보완한 새 품종이다. 원감은 만주 감초보다 줄기가 곧고 쓰러짐에 강하며 뿌리수가 많아 수확량도 만주 감초보다 높은 특징이 있다.Licorice means a perennial herbaceous plant belonging to the genus Glycyrrhiza, and the licorice used in the present invention is a plant of the genus Glycyrrhiza uralensis ), Manju liquorice ( Glycyrrhiza uralensis Fische) and European licorice ( Glycyrrhiza glabra Linne) is a new varieties that complement the functionality. Rice is stronger than Manchuria licorice and its stems are stronger than those of Manchuria licorice, and its yield is higher than that of Manchuria licorice because it has many roots.
민들레는 속씨식물문의 쌍자엽강에 속하는 다년생 초본 식물로, 안질방이, 무슨들레라고도 불린다. 꽃은 4-5월에 피며, 예로부터 어린 잎은 나물과 국거리로 식용해 왔다 (김일혁 및 성환길, 약이 되는 풀과 나무, 중앙대학교 출판부, p332, 1997). 또한, 민들레는 꽃이 피기 전에 전초를 건조한 것을 포공영 (김원, 자원식물학, 경북대학교 출판부, p190, 1987)이라 하며 한방에서는 강장, 해열, 이뇨, 건위, 거담, 해독 등에 이용되어 왔다 (홍석화, 한국의 토종 101가지, 웅진출판사, 1990, 18). 민들레의 맛과 성질은 쓰고 달며, 차갑다. 전초는 이담 작용이 있으며 위액의 분비를 빠르게 한다. 본 발명에서는 노랑민들레(Taraxacum officinale)를 사용하였다.Dandelion is a perennial herbaceous plant belonging to the dicotyledon of a herbaceous plant. Flowers are bloomed in April-May, and young leaves have been edible as herbs and herbs (Kim Il-hyuk and Seonghwan Gil, Medicinal Plums and Trees, Chungang University Press, p332, 1997). Dandelion has been used for the treatment of gangjeong, fever, diuretic, dryness, goddam, and detoxification in one room (Hong Sukhwa, Korea) 101 species of native species, Woongjin Publishing Co., 1990, 18). The taste and nature of dandelion is sweet and sweet, and it is cold. The outpost has a dysfunction and accelerates secretion of gastric juice. In the present invention, yellow dandelion ( Taraxacum officinale ) was used.
상기 감초 추출물 및 노랑민들레 추출물은 다양한 기관 또는 부분(예를 들어, 잎, 꽃, 뿌리, 줄기, 가지, 껍질 및 종자 등)으로부터 추출하여 얻을 수 있다. 본 발명에서 감초 추출물은 감초의 뿌리 부위를 원료로 하여 제조하는 것이 바람직하고, 노랑민들레 추출물은 노랑민들레의 지상부를 원료로 하여 제조하는 것이 바람직하다. 상기 용어 “지상부”는 꽃과 뿌리를 제거한 잎과 줄기 부위를 의미한다.The licorice extract and yellow dandelion extract can be obtained by extracting from various organs or parts (for example, leaves, flowers, roots, stems, branches, husks and seeds). In the present invention, the licorice extract is preferably prepared from the roots of licorice root as a raw material, and the yellow dandelion extract is preferably prepared from the ground part of yellow dandelion as a raw material. The term " above ground " refers to leaves and stem parts from which flowers and roots have been removed.
본 발명의 용어 "추출물"은 상기 감초 또는 노랑민들레의 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농충액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 구체적으로 본 발명의 상기 추출물은 추출 후 건조 분말 형태로 제조되어 사용될 수 있다.The term "extract" of the present invention refers to an extract obtained by extracting the licorice or yellow dandelion, a dilute or concentrated solution of the extract, a dried product obtained by drying the extract, a preparation or a purified product of the extract, Etc., the extract itself and extracts of all the formulations which can be formed using the extract. Specifically, the extract of the present invention may be prepared in the form of a dry powder after extraction.
본 발명의 상기 추출물은, 상기 식물의 천연, 잡종 또는 변종 식물로부터 추출될 수 있고, 식물 조직 배양물로부터도 추출이 가능하다.The extract of the present invention can be extracted from natural, hybrid or variant plants of the plant, and can also be extracted from plant tissue cultures.
본 발명의 상기 감초 또는 노랑민들레의 추출에 있어서, 상기 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있다.In the extraction of licorice or yellow dandelion of the present invention, the extraction method is not particularly limited, and extraction can be carried out according to a method commonly used in the art. Non-limiting examples of the extraction method include hydrothermal extraction, ultrasonic extraction, filtration, and reflux extraction. These may be performed alone or in combination with two or more methods.
본 발명에서 상기 감초 또는 노랑민들레를 추출하는 데 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 C1~C4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합물을 사용할 수 있으며, 구체적으로는 상기 감초 또는 노랑민들레를 물, C1~C4의 알코올 또는 이들의 혼합용매로 추출할 수 있으나, 이에 제한되는 것은 아니다. 본 발명에서 상기 저급 알코올은 에탄올일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the kind of the extraction solvent used for extracting licorice or yellow dandelion is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water; C 1 -C 4 lower alcohols such as methanol, ethanol, propyl alcohol and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol and propylene glycol; And hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or mixtures thereof. Specifically, the licorice or yellow dandelion can be extracted with water, a C 1 to C 4 alcohol, or a mixed solvent thereof, but is not limited thereto. In the present invention, the lower alcohol may be ethanol, but is not limited thereto.
본 발명의 일실시예에서는 세척 및 건조로 이물질이 제거된 감초 뿌리와 노랑민들레 지상부를 동결건조한 후 분쇄하여 물로 3회 반복하여 열수 추출하였다. 필요한 경우에는 당업계에 공지된 방법에 따라 여과, 농축 및 동결건조 등의 단계를 추가적으로 거쳐 분말로 제조될 수 있다.In one embodiment of the present invention, the ground portion of the licorice root and the yellow dandelion having the foreign substances removed by washing and drying were lyophilized, pulverized, and then subjected to hot water extraction by repeating three times with water. If necessary, the powder may be further subjected to steps such as filtration, concentration and freeze-drying according to methods known in the art.
본 발명의 일실시예에서는, 본 발명의 감초와 노랑민들레 추출물의 혼합물을 함유하는 조성물의 알코올성 위염 개선 효과를 확인하기 위해 알코올, 바람직하게는 에탄올 투여로 위 염증이 발생한 래트 동물모델에서 위 조직의 조직병리학적 평가 및 염증 발생 면적을 분석하였다.In one embodiment of the present invention, in order to confirm the effect of improving the alcoholic gastritis of the composition containing the mixture of licorice and yellow dandelion extract of the present invention, in a rat animal model in which gastric inflammation is caused by administration of alcohol, preferably ethanol, Histopathological evaluation and area of inflammation were analyzed.
도 1 및 2에 나타난 바와 같이, 에탄올만 투여한 대조군의 경우 위 조직의 염증, 출혈, 발적 및 부종이 발생하였고, 손상 부위 면적 또한 매우 넓었다. 단독 추출물 투여의 경우, 노랑민들레 추출물의 위 조직 염증 개선효과가 감초 추출물보다 우수하였다. 상기 단독 추출물 투여군과 동일한 양으로 투여하되 중량비를 달리하여 혼합한 혼합물 A, B 및 C를 각각 투여한 실험군에서는 특정 중량비에서 특이적인 상승효과가 나타남을 확인하였다.As shown in Figs. 1 and 2, in the case of the ethanol-only control group, inflammation, hemorrhage, erythema and edema of the stomach occurred and the area of the damaged area was also very wide. In the case of administration of the single extract, the effect of improving the stomach inflammation of the yellow dandelion extract was superior to that of the licorice extract. It was confirmed that there was a specific synergistic effect in the specific weight ratio in the experimental group administered with the mixture A, B and C, respectively, administered in the same amount as that of the single extract administration group.
구체적으로, 혼합물에서 노랑민들레 추출물의 중량비가 증가할수록 복합 상승효과가 증가되었다. 바람직한 혼합 중량비는 1:0.25 내지 1:4이고, 더욱 바람직하게는 1:1 내지 1:4이며, 가장 바람직한 혼합 중량비는 1:4일 수 있다. 특히, 감초 추출물과 노랑민들레 추출물의 혼합 중량비가 1:1 내지 1:4인 경우, 감초 추출물 또는 노랑민들레 추출물의 단독 투여군에서 나타난 위 조직 염증 개선 효과보다 뛰어난 효과를 나타내어 혼합에 따른 최대의 복합 상승효과가 나타남을 확인하였다. Specifically, the compound synergistic effect was increased as the weight ratio of the yellow dandelion extract to the mixture was increased. The preferred mixing weight ratio is 1: 0.25 to 1: 4, more preferably 1: 1 to 1: 4, and most preferably 1: 4. In particular, when the weight ratio of the licorice extract to the yellow dandelion extract is in the range of 1: 1 to 1: 4, the effect of improving the stomach inflammation in the single administration group of licorice extract or yellow dandelion extract is exerted, Effect was observed.
감초와 노랑민들레 추출물을 상기 범위를 벗어난 중량비로 혼합할 경우, 두 가지 추출물의 복합 상승효과가 감소하여 최적의 활성을 나타낼 수 없으므로(도 1 및 2), 상기 중량비 범위 내에서 두 가지 추출물을 혼합하는 것이 바람직하다.When the licorice and yellow dandelion extracts are mixed at a weight ratio out of the above range, the complex synergistic effect of the two extracts is reduced and the optimum activity can not be exhibited (FIGS. 1 and 2) .
또한, 도3에 나타난 바와 같이 혼합물 A, B 및 C를 각각 투여한 실험군 중 혼합물 B 및 C 투여군에서 iNOS의 발현이 현저하게 억제됨을 확인하였고, 특히 감초 추출물과 노랑민들레 추출물이 1:4의 중량비로 혼합된 혼합물 C군에서 iNOS 발현 억제 효과가 최대로 나타남을 확인하였다.In addition, as shown in FIG. 3, it was confirmed that the expression of iNOS was significantly inhibited in the mixture B and C of the experimental groups to which the mixtures A, B and C were respectively administered, and in particular, the licorice extract and the yellow dandelion extract had a weight ratio of 1: 4 , The inhibitory effect on iNOS expression was maximized in the mixture C group.
따라서, 감초 추출물과 노랑민들레 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물은 알코올로 유발된 위 조직의 염증을 현저하게 완화시켜 알코올성 위염 치료에 탁월한 효능이 있음을 알 수 있다.Therefore, the mixture of the licorice extract and the yellow dandelion extract at a weight ratio of 1: 1 to 1: 4 can remarkably alleviate the inflammation of the stomach tissue induced by alcohol, and thus has an excellent effect in the treatment of alcoholic gastritis.
본 발명에 있어서, “알코올성 위장관질환”은 알코올에 의한 위 손상으로 유발되는 모든 질환을 의마한다. 예를 들어, 알코올에 의해 유도된 급성 위점막 손상, 위궤양, 급성 위염 및 만성 위염으로 이루어진 군으로부터 선택한 1종 이상일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, " Alcoholic Gastrointestinal Disease " refers to any disease caused by alcohol-induced stomach injury. For example, it may be at least one selected from the group consisting of acute gastric mucosal injury induced by alcohol, gastric ulcer, acute gastritis and chronic gastritis, but is not limited thereto.
추가로, 본 발명의 감초 추출물 및 노랑민들레 추출물의 혼합물은 알코올성 간 손상에 대한 예방 효과를 나타낼 수 있다. In addition, the mixture of licorice extract and yellow dandelion extract of the present invention can exhibit a preventive effect against alcoholic liver damage.
간과 관련된 여러 질환들을 감별하기 위해서는 몇 가지 화학적 검사들을 종합적으로 해석하는 것이 필요한데, 이를 위하여 몇 가지 검사항목들을 묶어 간 기능 검사로 통칭한다. 주요 검사로는 GOT, GPT 등이 있고, 이외에도 총 단백질, 알부민, 암모니아 등의 항목을 더하여 검사하는 경우도 많다.In order to distinguish the various diseases related to the liver, it is necessary to comprehensively analyze several chemical tests. For this purpose, some test items are collectively referred to as liver function tests. Major tests include GOT and GPT. In addition, there are many cases in which total protein, albumin, and ammonia are added to the test.
GOT(glutamic oxaloacetic transaminase, 아스파르트산 아미노기전달효소)는 L-아스파르트산의 아미노기를 α-케토글루타르산으로 전달하여 옥살로아세트산과 L-글루탐산을 생성하는 가역반응을 촉매하는 효소이다. 간염, 심근경색 등의 진단 시 혈중에서의 이 효소 활성에 대한 측정이 자주 이용된다.GOT (glutamic oxaloacetic transaminase) is an enzyme that catalyzes the reversible reaction of producing oxaloacetic acid and L-glutamic acid by transferring the amino group of L-aspartic acid to? -Ketoglutaric acid. In the diagnosis of hepatitis and myocardial infarction, measurement of this enzyme activity in the blood is frequently used.
GPT(glutamic-pyruvic transaminase, 알라닌 아미노기전달효소)는 알라닌의 아미노기를 α-케토글루타르산에 전달하여 피루브산과 글루탐산 생성반응을 촉매하는 효소이다. 간·담도계 질환의 진단을 위해 혈액 중의 이 효소의 활성 측정이 자주 이루어진다.GPT (glutamic-pyruvic transaminase) is an enzyme that catalyzes pyruvic acid and glutamic acid production by transferring the amino group of alanine to α-keto glutaric acid. In order to diagnose liver and biliary system diseases, the activity of this enzyme in blood is frequently measured.
따라서, 본 발명에서는 알코올성 간 손상에 대한 개선 효과를 GOT 및 GPT 수치 측정을 통해 확인하였다. 도 4에 나타난 바와 같이, 본 발명의 감초 추출물 및 노랑민들레 추출물의 혼합물을 함유하는 조성물은 알코올, 바람직하게는 에탄올 투여로 증가된 GOT 및 GPT 수치를 현저하게 감소시킴을 확인하였다. 혼합물 투여군의 현저한 상승효과는 투여된 혼합물이 에탄올 보다 빠르게 흡수되어 GOT 및 GPT 수치를 감소시키기 때문에 나타나는 것으로 판단된다.Therefore, in the present invention, the improvement effect on alcoholic liver damage was confirmed by GOT and GPT measurement. As shown in FIG. 4, it was confirmed that the composition containing the mixture of the licorice extract and the yellow dandelion extract of the present invention markedly decreased the GOT and GPT levels, which were increased by the administration of alcohol, preferably ethanol. The remarkable synergistic effect of the group administered with the mixture appears to be due to the fact that the administered mixture is absorbed more rapidly than ethanol and reduces the GOT and GPT levels.
이상의 결과를 통해, 본 발명의 감초 추출물 및 노랑민들레 추출물의 혼합물은 알코올에 의한 위 손상 개선뿐만 아니라 간 손상 예방 효과를 나타내어 알코올의 과다 섭취로부터 위와 간을 동시에 보호할 수 있음을 알 수 있다.From the above results, it can be seen that the mixture of the licorice extract and yellow dandelion extract of the present invention not only improves the stomach damage caused by alcohol but also shows the effect of preventing liver damage, so that the stomach and liver can be protected simultaneously from the excessive consumption of alcohol.
본 발명의 약학적 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
본 발명에 따른 약학적 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition according to the present invention can be formulated in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like oral preparation, external preparation, suppository and sterilized injection solution according to a conventional method Can be used.
본 발명의 조성물에 함유될 수 있는 담체, 부형제 및 희석제로는 락토오즈(lactose), 덱스트로즈, 수크로스(sucrose), 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Examples of carriers, excipients and diluents that may be contained in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose or lactose , Gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
상기 본 발명의 약학적 조성물은 약제학적으로 유효한 양으로 투여한다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
본 발명에서 용어 "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 감염된 바이러스 종류, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다.The term "pharmaceutically effective amount " as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will vary depending on the species and severity, age, sex, , The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art.
본 발명의 약학적 조성물은 단독으로, 또는 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, hormone therapy, drug therapy and biological response modifiers.
상기 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다.The composition can be administered to mammals such as rats, mice, livestock, humans, and the like in a variety of routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
본 발명의 감초 추출물과 노랑민들레 추출물의 혼합물을 식품 첨가물로 사용할 경우, 상기 혼합물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합량은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에는 본 발명의 조성물은 원료에 대하여 0.01 ~ 10 중량%, 바람직하게는 0.05 ~ 1 중량%의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하로도 사용될 수 있다.When the mixture of licorice extract and yellow dandelion extract of the present invention is used as a food additive, the mixture can be used as it is, or can be used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, in the production of food or beverage, the composition of the present invention is added in an amount of 0.01 to 10% by weight, preferably 0.05 to 1% by weight based on the raw material. However, in the case of long-term ingestion intended for health and hygiene purposes or for the purpose of controlling health, the amount can also be used in the above-mentioned range.
상기 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스 및 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강기능식품은 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알코올 및 비타민 복합제 중 어느 하나의 형태일 수 있다.The health functional food may contain flavoring agents such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and thickening agents (cheese, chocolate etc.), pectic acid and its salts, alginic acid and its salts, Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It can also contain natural fruit juices and pulp for the production of fruit juices and vegetable drinks. These components may be used independently or in combination. The health functional food may be any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcohol and vitamin .
본 발명의 건강 음료 조성물은 감초 추출물과 노랑민들레 추출물의 혼합물을 함유하는 것 외에는 액체성분에는 특별한 제한은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The health beverage composition of the present invention is not particularly limited to a liquid ingredient except that it contains a mixture of licorice extract and yellow dandelion extract, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages.
또한, 상기 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, “식품첨가물”로서의 적합여부는 다른 규정이 없는 한 식품의약품안정청에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health functional food may further include food additives, and the suitability of the food functional food as a " food additive " is not limited to the corresponding items in general rules and general test methods approved by the Food and Drug Administration Shall be determined according to the relevant standards and standards.
상기 “식품첨가물공전”에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산 칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합 제제류 등을 들 수 있다.Examples of the products that have been used in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, sensory coloring matter, licorice extract, crystalline cellulose, high- - Mixed preparations such as a sodium glutamate preparation, a noodle-added alkaline agent, a preservative preparation, a tar coloring agent and the like.
하기의 실시예를 통하여 본 발명을 더욱 구체적으로 설명하기로 하지만, 하기의 실시예가 본 발명의 범위를 제한하는 것은 아니며, 이는 본 발명의 이해를 돕기 위한 것으로 해석되어야 할 것이다.The present invention will now be described more specifically with reference to the following examples. However, the following examples should not be construed as limiting the scope of the present invention, but should be construed to facilitate understanding of the present invention.
1-1. 감초 뿌리 추출물 및 노랑민들레 지상부 추출물의 제조1-1. Preparation of Extracts of Licorice Root Extract and Yellow Dandelion
수확한 감초의 뿌리와 노랑민들레의 지상부를 물로 세척하고 동결건조기(Martin Christ, Osterode, Germany)로 동결건조하였다. 동결건조된 시료를 분쇄 후 각각의 시료 150g에 물 1,000ml를 첨가하여 3시간, 3회 반복하여 열수추출하였다. 추출물은 와트만 (Whatman 46cm) 여과지를 이용하여 불용성 물질을 제거하고, 여과된 추출물은 회전감압농축기(Heidolph, Germanay)로 60℃에서 감압농축하였다. 감압농축된 추출물의 용매를 완전히 제거하기 위하여 정제수 50 ml를 넣어 현탁시킨 후 동결건조기를 이용하여 감초 뿌리 추출 동결건조물 27.5g과 노랑민들레 지상부 추출 동결건조물 61.3g을 수득하였다 (감초 추출물 수율: 18.3%, 노랑민들레 추출물 수율: 40.9%).The ground portion of the harvested licorice root and yellow dandelion was washed with water and lyophilized with a freeze dryer (Martin Christ, Osterode, Germany). After lysing the lyophilized sample, 1,000 ml of water was added to 150 g of each sample, and the mixture was subjected to hot extraction three times for 3 hours. The extracts were removed with insoluble materials using Whatman 46 cm filter paper, and the filtered extracts were concentrated under reduced pressure at 60 ° C with a rotary evaporator (Heidolph, Germanay). In order to completely remove the solvent of the concentrated extract, the supernatant was suspended in 50 ml of purified water, and 27.5 g of the lyophilized root extract-extracted freeze-dried product and 61.3 g of the yellow dandelion ground freeze-dried extract were obtained using a freeze dryer (yield of licorice extract: 18.3% , Yield of yellow dandelion extract: 40.9%).
1-2. 실험 동물1-2. Experimental animal
7주령 된 Spraque-Dawley 수컷 래트를 (주)오리엔트바이오로부터 구입하였다. 22℃에서 명/암 주기를 12시간 간격으로 설정하고, 식이와 물을 자유롭게 공급하여 1 주일간 기본식이로 적응시켰다.Seven-week-old Spraque-Dawley male rats were purchased from Orient Bio. The light / dark cycle was set at 12 hours at 22 ° C, and the diet and water were freely fed and adapted to the basic diet for one week.
알코올성 위염 개선 효과의 확인Identification of alcoholic gastritis improvement
2-1. 실험군 설정 및 시료 투여2-1. Experimental set-up and sample administration
상기 실시예 1-2의 실험동물을 각 군당 5마리씩, 아무것도 처리하지 않은 정상군, 5.0g/kg의 에탄올만을 투여한 대조군, 위염치료제로 사용중인 레바미피드(rebamipide)를 5.0g/kg의 에탄올에 용해하여 투여한 양성대조군 및 5.0g/kg의 에탄올에 용해된 각각의 실험시료를 투여한 5개의 실험군으로 나누어 실험을 진행하였다. 5개의 실험군에 대해 투여된 실험시료의 정보는 하기 표 1에 기재된 바와 같다. The experimental animals of Example 1-2 were divided into five groups, normal control group, 5.0 g / kg ethanol alone, rebamipide as a gastritis treatment, 5.0 g / kg The experimental group was divided into five experimental groups, each of which was administered with a test group dissolved in ethanol and a test group dissolved in 5.0 g / kg of ethanol. The information of the experimental samples administered for the five experimental groups is as shown in Table 1 below.
실험동물을 12시간 절식시킨 후 실험시료를 에탄올(5.0g/kg)로 용해하여 1회 경구투여하고, 1시간 후에 에테르 마취하여 개복 후 심장 채혈 및 위 조직을 적출하였다.Experimental animals were fasted for 12 hours. The experimental samples were dissolved in ethanol (5.0 g / kg) and then orally administered once. After 1 hour, the animals were anesthetized with ether, and cardiac blood collection and stomach tissues were extracted.
지상부 추출물Yellow dandelion
Above Ground Extract
2-2. 위 조직의 조직병리학적 평가 및 염증 발생 면적 분석2-2. Histopathological evaluation of stomach tissue and analysis of inflammation area
각 군에서 적출한 위 조직을 고정하여 손상된 범위 및 손상 정도를 관찰하였다. 그 결과, 도 1에 나타난 바와 같이 에탄올만 투여한 대조군의 경우, 위 조직의 염증, 출혈, 발적 및 부종이 발생하였고 손상 부위 면적 또한 매우 넓었다. 이러한 위 조직 손상은 혼합물 B 및 C 투여군에서 눈에 띄게 회복되었다.The stomach tissues extracted from each group were fixed and the degree of damage and degree of damage were observed. As a result, as shown in Fig. 1, in the case of the control group in which only ethanol was administered, inflammation, hemorrhage, erythema and edema occurred in the stomach tissue and the area of the damaged area was also very wide. These stomach injuries were noticeably restored in Mixture B and C treatment groups.
적출한 위 조직의 염증 발생 면적을 백분율로 환산하여 계산한 결과, 도 2에 나타난 바와 같이 감초 투여군 및 노랑민들레 투여군의 염증 발생 면적은 각각 43.3% 및 31.0%였고, 혼합물 A 투여군, 혼합물 B 투여군 및 혼합물 C 투여군의 염증 발생 면적은 41.9% 및 29.6% 및 20.2%였다.As shown in FIG. 2, the areas of inflammation in the licorice and yellow dandelion groups were 43.3% and 31.0%, respectively. As shown in FIG. 2, the area of inflammation was 43.3% and 31.0% The area of inflammation in the mixture C administration group was 41.9%, 29.6% and 20.2%.
이를 통해, 다른 실험군들에 비해 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:4의 중량비로 혼합된 혼합물 C군에서 상승 효과가 최대로 나타나 위 조직 손상이 현저하게 완화됨을 확인하였다.As a result, it was confirmed that the synergistic effect was maximized in the mixture C group in which the weight ratio of 1: 4 of the licorice root extract and the yellow dandelion root extract was higher than that of the other experimental groups, and the gastric tissue damage was remarkably alleviated.
2-3. 위 조직의 염증관련 단백질의 발현 억제 효과 확인2-3. Confirming the effect of inhibiting the expression of inflammatory proteins in gastric tissues
감초 뿌리 추출물과 노랑민들레 지상부 추출물의 혼합물 투여에 의한 염증 관련 단백질(iNOS)의 발현 변화를 평가하기 위해 웨스턴 블롯(Western blot) 실험방법으로 단백질량을 측정하여 확인하였다.The amount of protein was measured by Western blot method to evaluate the expression of inflammation - related protein (iNOS) by administration of mixture of licorice root extract and yellow dandelion root extract.
10 ㎍의 단백질을 SDS-폴리아크릴아미드 겔을 이용하여 전기영동으로 분리한 후, 아크릴아미드 겔을 니트로셀룰로오스 멤브래인으로 옮겼다. 그 다음 5% 스킴 밀크(skim milk)를 함유한 TBS-T (TBS에 용해된 0.5% 트윈 20)에 담구어 1시간 처리한 후 TBS-T로 5분마다 5회 세척하였다. 준비된 멤브래인에 1차 항체를 처리하여 4℃에서 하룻밤 동안 둔 다음 TBS-T로 10분마다 5회 세척하였다. 처리된 1차 항체에 맞는 2차 항체 (TBS-T로 1:5000로 희석해서 사용)를 사용하여 상온에서 1시간 30분 반응시킨 후, TBS-T로 10분마다 5회 세척하였다. ECL 용액으로 반응시킨 후 Davinch-ChemiTM Chemiluminescence Imaging system (Davinch-K Co., Ltd., 서울, 대한민국)에 감광시켜 단백질 발현을 확인한 다음, 해당 밴드를 ATTO Densitograph Software (ATTO Corporation, Tokyo, Japan) 프로그램을 사용하여 정량하였다.10 [mu] g of protein was separated by electrophoresis using SDS-polyacrylamide gel, and the acrylamide gel was transferred to a nitrocellulose membrane. The cells were then immersed in TBS-T (0.5
그 결과, 도 3에 나타난 바와 같이 실험군 중 혼합물 B 및 C 투여군에서 iNOS의 발현이 현저하게 억제됨을 확인하였고, 특히 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:4의 중량비로 혼합된 혼합물 C군에서 iNOS 발현 억제 효과가 최대로 나타남을 확인하였다.As a result, as shown in FIG. 3, it was confirmed that the expression of iNOS was significantly suppressed in the mixture group B and C in the experimental group, and in particular, in the mixture C group in which the licorice root extract and the yellow dandelion root extract were mixed at a weight ratio of 1: and iNOS expression inhibition effect was maximized.
상기 결과를 통해 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:1 내지 1:4의 중량비로 혼합된 조성물이 알코올성 위염을 치료하는데 매우 유용함을 확인하였다.From the above results, it was confirmed that a composition in which the licorice root extract and the yellow dandelion ground extract are mixed at a weight ratio of 1: 1 to 1: 4 is very useful for treating alcoholic gastritis.
혈청 중 간 기능 지표효소 활성 측정Measurement of serum liver function index enzyme activity
상기 실시예 2-1의 실험동물로부터 채혈한 혈액에서 GOT (glutamic oxaloacetic transaminase) 및 GPT (glutamic-pyruvic transaminase) 활성을 제조사의 지시에 따라 진단 키트(Procedure No. 505, Sigma Chemical Co., St Louis, MO)를 사용하여 비색법으로(colorimetrically) 측정하였다.The activity of glutamic-pyruvic transaminase (GOT) and glutamic-pyruvic transaminase (GOT) in the blood obtained from the experimental animal of Example 2-1 was measured using a diagnostic kit (Procedure No. 505, Sigma Chemical Co., St. Louis, , ≪ / RTI > MO) as colorimetrically.
그 결과, 도 4에 나타난 바와 같이 에탄올 투여로 GOT 및 GPT 수치가 증가하였고(대조군), 혼합물 A군, B군 및 C군은 감초 및 노랑민들레를 각각 단독으로 투여한 군보다 GOT 및 GPT 수치가 현저하게 감소됨을 확인하였다. 혼합물 투여군의 현저한 상승효과는 투여된 혼합물이 에탄올 보다 빠르게 흡수되어 GOT 및 GPT 수치를 감소시키기 때문에 나타나는 것으로 판단되며, 이를 통해 본 발명의 감초 뿌리 추출물 및 노랑민들레 지상부 추출물의 혼합물은 알코올에 의한 간 손상을 효과적으로 예방할 수 있음을 알 수 있다.As a result, as shown in FIG. 4, the GOT and GPT values were increased by ethanol administration (control group), and the GOT and GPT values of the mixture group A, B and C groups were higher than those of the licorice and yellow dandelion alone groups . The remarkable synergistic effect of the mixture administration group appears to be due to the fact that the administered mixture is absorbed more rapidly than ethanol to reduce the GOT and GPT levels. Thus, the mixture of the licorice root extract of the present invention and the yellow dandelion topsoil extract, Can be effectively prevented.
제조예 1: 약학적 제제의 제조Preparation Example 1: Preparation of pharmaceutical preparations
1-1. 산제의 제조1-1. Manufacture of Powder
감초 뿌리 추출물 0.5g과 노랑민들레 지상부 추출물 2.0g의 혼합물 또는 감초 뿌리 추출물 1.25g과 노랑민들레 지상부 추출물 1.25g의 혼합물을 유당 1g과 혼합한 후, 기밀포에 충진하여 산제를 제조하였다.A mixture of 0.5 g of the licorice root extract and 2.0 g of the yellow dandelion root extract or 1.25 g of the licorice root extract and 1.25 g of the yellow dandelion root extract was mixed with 1 g of lactose and filled in airtight bags to prepare powders.
1-2. 정제의 제조1-2. Manufacture of tablets
감초 뿌리 추출물 25mg과 노랑민들레 지상부 추출물 100mg의 혼합물 또는 감초 뿌리 추출물 62.5mg과 노랑민들레 지상부 추출물 62.5mg의 혼합물을 옥수수 전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2 ㎎과 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.A mixture of 25 mg of the licorice root extract and 100 mg of the yellow dandelion root extract or 62.5 mg of the licorice root extract and 62.5 mg of the yellow dandelion root extract was mixed with 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate, Tablets were prepared by tabletting according to the manufacturing method.
1-3. 캡슐제의 제조1-3. Preparation of capsules
감초 뿌리 추출물 0.5g과 노랑민들레 지상부 추출물 2.0g의 혼합물 또는 감초 뿌리 추출물 1.25g과 노랑민들레 지상부 추출물 1.25g의 혼합물을 옥수수 전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2 ㎎과 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.A mixture of 0.5 g of the licorice root extract and 2.0 g of the yellow dandelion ground extract, or a mixture of 1.25 g of the licorice root extract and 1.25 g of the yellow dandelion ground extract was mixed with 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate, The capsules were filled in gelatin capsules according to the preparation method of capsules.
1-4. 주사액제의 제조1-4. Injection preparation
적당한 주사용 염화나트륨 BP에 감초 뿌리 추출물 2.5 ㎍/㎖와 노랑민들레 추출물 10 ㎍/㎖의 혼합물 또는 감초 뿌리 추출물 6.25 ㎍/㎖와 노랑민들레 지상부 추출물 6.25 ㎍/㎖의 혼합물을 용해시키고, 생성된 용액의 pH를 묽은염산 BP를 사용하여 pH 3.5로 조절하고, 주사용 염화나트륨 BP(최대 1 ㎖)를 사용하여 용적을 조절하여 충분히 혼합하였다. 용액을 투명 유리로 된 5 ㎖ 타입 I 앰플 중에 충전시키고, 유리를 용해시킴으로써 공기의 상부 격자하에 봉입시키고, 120 ℃에서 15분 이상 오토클래이브시켜 살균하여 주사액제를 제조하였다.A mixture of 2.5 g / ml of licorice root extract and 10 .mu.g / ml of yellow dandelion extract or 6.25 .mu.g / ml of licorice root extract and 6.25 .mu.g / ml of yellow dandelion root extract was dissolved in suitable injectable sodium chloride BP and the resulting solution The pH was adjusted to pH 3.5 with diluted hydrochloric acid BP and mixed well by adjusting the volume using injectable sodium chloride BP (up to 1 ml). The solution was filled in a 5 ml type I ampoule made of transparent glass, sealed in an upper lattice of air by dissolving the glass, sterilized by autoclaving at 120 DEG C for 15 minutes or longer, and an injection solution was prepared.
제조예 2: 건강식품의 제조Preparation Example 2: Preparation of health food
2-1. 조리용 양념의 제조2-1. Manufacture of cooking seasonings
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 4:1 내지 1:4의 중량비로 혼합한 혼합물을 0.2 ~ 10 중량%로 첨가하여 건강 증진용 조리용 양념을 제조하였다.A mixture of the licorice root extract and the yellow dandelion ground top extract at a weight ratio of 4: 1 to 1: 4 was added in an amount of 0.2 to 10% by weight to prepare a cooking sauce for health promotion.
2-2. 토마토 2-2. tomato 케찹ketchup 및 소스의 제조 And source
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물 0.2 ~ 1.0 중량%를 토마토 케찹 또는 소스에 첨가하여 건강 증진용 토마토 케찹 또는 소스를 제조하였다.0.2-1.0% by weight of a mixture of a licorice root extract and a yellow dandelion ground top extract mixture at a weight ratio of 1: 1 to 1: 4 was added to tomato ketchup or sauce to prepare health improvement tomato ketchup or sauce.
2-3. 밀가루 식품의 제조2-3. Manufacture of flour food products
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물 0.1 ~ 5.0 중량%를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.1 to 5.0% by weight of a mixture of a licorice root extract and a yellow dandelion ground top extract mixture at a weight ratio of 1: 1 to 1: 4 was added to wheat flour, and bread, cake, cookies, crackers and noodles were prepared Health enhancing foods were prepared.
2-4. 스프 및 육즙 (gravies)의 제조2-4. Manufacture of soups and gravies
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 4:1 내지 1:4의 중량비로 혼합한 혼합물 0.1 ~ 1.0 중량%를 스프 및 육즙에 첨가하여 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1 to 1.0 wt.% Of a mixture of licorice root extract and yellow dandelion ground top extract mixture at a weight ratio of 4: 1 to 1: 4 was added to soup and juice to prepare health promotion meat product, noodle soup and juice.
2-5. 그라운드 비프 (ground beef)의 제조2-5. Manufacture of ground beef
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물 10 중량%를 그라운드 비프에 첨가하여 건강 증진용 그라운드 비프를 제조하였다.A ground beef for health promotion was prepared by adding 10% by weight of a mixture of licorice root extract and yellow dandelion ground top extract at a weight ratio of 1: 1 to 1: 4 to ground beef.
2-6. 유제품 (dairy products)의 제조2-6. Manufacture of dairy products
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물 0.1 ~ 1.0 중량%를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.0.1 to 1.0% by weight of a mixture of a licorice root extract and a yellow dandelion topsoil extract at a weight ratio of 1: 1 to 1: 4 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
2-7. 선식의 제조2-7. Manufacture of wires
현미, 보리, 찹쌀, 율무를 공지된 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.The brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the powder was prepared into a powder having a particle size of 60 mesh by a pulverizer.
검정콩, 검정깨, 들깨도 공지된 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black beans, black sesame seeds, and perilla seeds were steamed and dried by a known method, and then they were prepared into powders having a particle size of 60 mesh by a pulverizer.
감초 뿌리 추출물과 노랑민들레 지상부 추출물을 1:1 내지 1:4의 중량비로 혼합한 혼합물을 진공 농축기에서 감압농축하고, 분무, 열풍 건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The mixture obtained by mixing the licorice root extract and the yellow dandelion ground top extract in a weight ratio of 1: 1 to 1: 4 was concentrated under reduced pressure in a vacuum concentrator, sprayed and dried with a hot air drier, and the resulting dried product was pulverized into 60- ≪ / RTI >
상기에서 제조한 곡물류, 종실류 및 감초 추출물의 건조분말을 다음의 비율로 배합하여 제조하였다.The above-prepared cereal grains, seeds and dried powder of the licorice extract were blended in the following proportions.
곡물류 (현미 30 중량%, 율무 15 중량%, 보리 20 중량%),Cereals (30% by weight of brown rice, 15% by weight of yulmu, 20% by weight of barley)
종실류 (들깨 7 중량%, 검정콩 8 중량%, 검정깨 7 중량%),Seeds (7% by weight of perilla, 8% by weight of black beans, 7% by weight of black sesame seeds)
감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:1 내지 1:4의 중량비로 혼합된 혼합물의 건조분말 (1 중량%),Dried powder (1% by weight) of the mixture in which the licorice root extract and the yellow dandelion topsoil extract were mixed at a weight ratio of 1: 1 to 1: 4,
영지 (0.5 중량%), 및Manure (0.5% by weight), and
지황 (0.5 중량%)(0.5% by weight)
2-8. 탄산음료의 제조2-8. Manufacture of carbonated drinks
설탕 5~10%, 구연산 0.05 ~ 0.3 %, 카라멜 0.005 ~ 0.02 %, 비타민 C 0.1 ~ 1 %의 첨가물을 혼합하고, 여기에 79 ~ 94 %의 정제수를 섞어서 시럽을 만들었다. 상기에서 제조한 시럽을 85 ~ 98 ℃에서 20 ~ 180초 동안 살균하여 냉각수와 1 : 4의 비율로 혼합시킨 다음, 탄산가스를 0.5 ~ 0.82 % 주입하여 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:1 내지 1:4의 중량비로 혼합된 혼합물을 함유하는 탄산음료를 제조하였다.Syrup was prepared by mixing additives of 5 to 10% of sugar, 0.05 to 0.3% of citric acid, 0.005 to 0.02% of caramel and 0.1 to 1% of vitamin C and 79 to 94% of purified water. The syrup prepared above was sterilized at 85 to 98 ° C for 20 to 180 seconds and mixed with cooling water at a ratio of 1: 4. Then, carbonic acid gas was injected at 0.5 to 0.82%, and the extracts of licorice root extract and yellow dandelion ground- 1 to 1: 4 by weight.
2-9. 건강음료의 제조2-9. Manufacture of health drinks
액상과당 (0.5 %), 올리고당 (2 %), 설탕 (2 %), 식염 (0.5 %), 물 (75 %)과 같은 부재료에 감초 뿌리 추출물과 노랑민들레 지상부 추출물이 1:1 내지 1:4의 중량비로 혼합된 혼합물을 균질하게 배합하여 순간 살균을 한 후 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.The extracts of licorice root and yellow dandelion ground top extracts were mixed in a ratio of 1: 1 to 1: 4 (1: 1) to fructose such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2% , The mixture was homogenized and sterilized instantaneously, and then packaged in a glass bottle, plastic bottles and plastic bottles to prepare a health drink.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170104866A KR102019974B1 (en) | 2017-08-18 | 2017-08-18 | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170104866A KR102019974B1 (en) | 2017-08-18 | 2017-08-18 | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190019660A true KR20190019660A (en) | 2019-02-27 |
| KR102019974B1 KR102019974B1 (en) | 2019-09-10 |
Family
ID=65561052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170104866A KR102019974B1 (en) | 2017-08-18 | 2017-08-18 | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102019974B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090040631A (en) * | 2007-10-22 | 2009-04-27 | 인제대학교 산학협력단 | Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient |
-
2017
- 2017-08-18 KR KR1020170104866A patent/KR102019974B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090040631A (en) * | 2007-10-22 | 2009-04-27 | 인제대학교 산학협력단 | Composition for preventing or treating immune disease comprising dandelion water extract as an active ingredient |
Non-Patent Citations (1)
| Title |
|---|
| 논문1* * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102019974B1 (en) | 2019-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
| KR100771524B1 (en) | Composition for improving liver function comprising herbal mixture extract | |
| KR101484021B1 (en) | A Composition Comprising the extract of combined herbs including Curcuma Longa L. for immuno-stimulating activity | |
| KR101902932B1 (en) | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum | |
| KR100771525B1 (en) | Composition for removing hangover comprising herbal mixture extract | |
| KR101126164B1 (en) | A compositions for the prevention and treatment of inflammatory diseases containing essential oil isolated from rhizome of Curcuma wenyujin as an active ingredient | |
| KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
| KR20190033828A (en) | Compositions for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising herbal extracts | |
| KR20140129492A (en) | Compositions Comprising a Leaf Extract of Cudrania tricuspidata for the Prevention and Treatment of Arthritis disease | |
| KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
| KR20200053016A (en) | Pharnaceutical composition for prevention or treatment of diabetes comprising the mixed extract of vegetable natural products having the effect on removal of swelling and health functional food for prevention or improvement of diabetes comprising the same | |
| KR101070476B1 (en) | Composition containing extract of black onion for prevention and treatment of Gout or Hyperuricemia | |
| KR102019974B1 (en) | A composition for preventing, improving or treating alcoholic gastro-intestinal disease comprising the extracts from licorice and dandelion | |
| KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
| KR102014922B1 (en) | Composition for improving digestive functions comprising glabridin from Liquorice | |
| KR102122408B1 (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising roasted Glycyrrhiza uralensis extract as effective component | |
| KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
| KR101282356B1 (en) | Composition comprising Acanthopanacis Cortex butanol fraction for preventing or treating gastrointestinal disease | |
| KR100888068B1 (en) | Compositions for suppressing obesity | |
| KR100760386B1 (en) | Composition comprising the extract of ACP mixed crude drugs for preventing and treating arthritis | |
| KR101531922B1 (en) | Composition containing improvement of gastric disease by using the ethanolic extract of Rumex acetosa L. | |
| KR101618215B1 (en) | The pharmaceutical compositions for prevention or treatment of male infertility containing Rehmannia glutinosa Liboschitz var.purpurae Makino, Lycium chinense Miller, Aquillaria agallocha Roxburgh, Poria cocos Wolf, Panax ginseng C.A. Meyer and honey as a active ingredient | |
| KR102302047B1 (en) | Composition for hepatoprotective and ameliorating hangover | |
| KR101565909B1 (en) | Composition for prevention and treatment of hepatic ischemia-reperfusion injury comprising extracts of Acanthopanax sp. | |
| KR101052067B1 (en) | Inflammatory disease prevention or treatment composition containing wild vegetable extract as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |